Nachrichten zur Exact Sciences Corp. Aktie

Exact Sciences stock drops as Guardant Health test supported by FDA panel…

EXAS earnings call for the period ending March 31, 2024.…

Exact Sciences Shares Drop 10% on Earnings Miss…

Exact Sciences (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth,…

…

A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part…

Exact Sciences EVP sells $140k in company stock…

Citi sees Exact Sciences shares climbing after rivals data disappoints…

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…

…

Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…

Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…